middle.news
Lumos Diagnostics Accelerates Growth with 71% Revenue Surge and BARDA Partnership
6:29pm on Sunday 1st of June, 2025 AEST
•
Healthcare
Read Story
Lumos Diagnostics Accelerates Growth with 71% Revenue Surge and BARDA Partnership
6:29pm on Sunday 1st of June, 2025 AEST
Key Points
71% revenue growth to US$2.9 million in Q2 FY25
200% increase in product revenue, led by ViraDx sales
Secured US$3 million BARDA funding for FebriDx CLIA waiver trial
CPT PLA reimbursement code approved for FebriDx at US$41.38 per test
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE